DV
Dividend Vision

ALXO — Alx Oncology Holdings

Alx Oncology Holdings (ALXO)

Total return is -93.5% over the past 6.1 years, 255.5 points behind SPY at 162.0%. Its deepest 1-year drawdown was 50.5%.

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company developing cancer therapies, primarily its lead candidate Evorpacept, a CD47 blocking therapeutic in combination studies for gastric cancer and other solid tumors, with collaboration agreements involving major pharmaceutical partners including Jazz Pharmaceuticals and Sanofi. The company does not currently distribute to shareholders. ALX Oncology appeals to investors seeking exposure to early-stage biotech with potential for significant gains or losses, as clinical-stage companies carry substantial development risk and typically do not generate near-term income.

ALXO key facts

Asset type
Stock
Asset class
Equity
Inception date
07/17/2020
Last close
$1.96
Market cap
$282,582,112
Average volume
584160.0
Beta
0.432
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.49